-
1 Comment
INKON Life Technology Co., Ltd is currently in a long term downtrend where the price is trading 4.7% below its 200 day moving average.
From a valuation standpoint, the stock is 159.2% more expensive than other stocks from the Consumer Defensive sector with a price to sales ratio of 17.6.
INKON Life Technology Co., Ltd's total revenue rose by 38.8% to $204M since the same quarter in the previous year.
Its net income has increased by 1.1% to $16M since the same quarter in the previous year.
Finally, its free cash flow grew by 162.3% to $42M since the same quarter in the previous year.
Based on the above factors, INKON Life Technology Co., Ltd gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Medical Devices |
| Exchange | SHE |
| ISIN | CNE100000XF6 |
| CurrencyCode | CNY |
| Beta | 1.19 |
|---|---|
| Market Cap | 7B |
| PE Ratio | 50.56 |
| Target Price | 11.97 |
| Dividend Yield | None |
INKON Life Technology Co., Ltd. focuses on building an ecological platform for chain of pre-diagnosis/treatment/health providing medical services for tumors in China and internationally. The company engages in the research, development, innovation, and services of scenarios and equipment medical devices. The company was formerly known as Starmap Medicine and Technology Co., Ltd. and changed its name to INKON Life Technology Co., Ltd. in July 2019. INKON Life Technology Co., Ltd. was founded in 1998 and is headquartered in Qingdao, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300143.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
